MetaVia Q2 net loss widens on higher R&D spending

MetaVia

06/08/2026 21:39

Overview
US biotechnology firm's Q2 net loss widened yr/yr on higher R&D spending for DA-1726
Company completed dose titration in Phase 1 DA-1726 trial; topline data expected Q4 2026
Cash and cash equivalents rose to $12.6 mln; company expects funding to last through 2026

Outlook
MetaVia expects topline data from DA-1726 Phase 1 Part 3 study in Q4 2026
Company plans End-of-Phase 2 FDA meeting for vanoglipel in H2 2026
MetaVia expects its cash position will fund operations through 2026

Result Drivers
HIGHER R&D SPENDING - Co attributed increased Q2 operating expenses to higher direct R&D costs for DA-1726 product development
DOSE TITRATION COMPLETION - Co completed dose titration in Phase 1 Part 3 study of DA-1726, with all active patients reaching highest planned dose levels
POSITIVE CLINICAL DATA - Co presented data showing up to 9.1% mean weight loss after eight weeks of DA-1726 treatment, reinforcing confidence in drug's profile

Company press release: ID:nPn76rKF6a

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
 
$5.32 mln
 
Q2 Income from Operations
 
-$5.39 mln
 
Q2 Operating Expenses
 
$5.39 mln
 
Q2 Pretax Loss
 
$5.32 mln
 

Reuters Recommended Reads
Aug 6 - Avalo Therapeutics Q2 net loss widens, driven by higher R&D expenses
Aug 6 - vTv Therapeutics Q2 net loss widens on higher trial costs
Aug 4 - Dianthus Therapeutics Q2 net loss widens as R&D costs rise

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)